

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 13, 2008

Arrowhead Research Corporation

(Exact name of registrant as specified in its charter)

0-21898

(Commission File Number)

Delaware

(State or other jurisdiction of incorporation)

46-0408024

(IRS Employer Identification No.)

201 South Lake Avenue, Suite 703, Pasadena , California 91101

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (626) 304-3400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

EXPLANATORY NOTE

This amendment number 1 has been filed to include five slides that were inadvertently entitled from the previous Form 8-K filing due to filer error.

Item 8.01. Other Events.

On March 13, 2008, Christopher Anzalone, the Chief Executive Officer of Arrowhead Research Corporation (the “**Company**”), is scheduled to make a presentation following the Company’s regularly scheduled 2008 Annual Meeting of Stockholders. During his presentation, Dr. Anzalone plans to provide a slide presentation, “Creating Value by Building Nanobusiness from Nanoscience Presentation,” attached hereto as Exhibit 99.1, incorporated herein by reference and filed pursuant to Regulation FD under Item 9.01 of this Current Report on Form 8-K. The materials are also posted on the registrant’s website, www.arrowheadresearch.com.

This Current Report on Form 8-K contains forward-looking statements concerning future events and performance of the Company. When used in this report, the words “intends,” “estimates,” “anticipates,” “believes,” “plans,” “may,” “will,” “should,” “projects” or “expects” and similar expressions are included to identify forward-looking statements. These forward-looking statements are based on our current expectations and assumptions and many factors could cause our actual results to differ materially from those indicated in these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. Readers should review carefully the risk factors identified under the caption “Risk Factors” in the Company’s recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. The Company disclaims any intent to update or announce revisions to any forward-looking statements to reflect actual events or developments.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Exhibit Description</u>
99.1	“Creating Value by Building Nanobusiness from Nanoscience Presentation” made on March 13, 2008 by Christopher Anzalone following the Company’s 2008 Annual Meeting of Stockholders

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 13, 2008

ARROWHEAD RESEARCH CORPORATION

By: /s/ Paul McDonnel
Paul McDonnel
Chief Financial Officer



Arrowhead Research
CORPORATION

*Creating Value by Building
Nanobusiness from Nanoscience*

3/13/08



Safe Harbor Statement

This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including, without limitation, our developmental stage and limited operating history, our ability to successfully develop products, rapid technological change in our markets, demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.


3/13/08



Market Opportunity: The Next Industrial Revolution




MicroElectroMechanical (MEMS) device
10 - 100 μm wide



Quantum Corral of 48 Iron Atoms ~1.5 μm



Red blood cells ~1.5 μm




Zone Plate x-ray "lens" spacing ~35 nm



Complexes between double-stranded DNA and the archaeal chromatin protein
Protein ~ 2 - 100 nm long

Carbon Nanotube ~1.3 nm diameter



•The US Government is investing over \$1 billion a year to fund nanotechnology research

•Dozens of new nano-research centers have started since 2000

•Paradigm-shifting technology that is applicable across multiple industries

•Attractive new company and roll-up opportunities


Arrowhead Key Value Drivers

- *Large Market Opportunity*
- *Model that Exploits Inefficient Market*
- *Execution*
- *Scalability*

3/13/08



Arrowhead Capitalizes on Market Imbalances



3/13/08



Arrowhead Drop-in Solutions

We are not a hotel

- *Initial management team*
- *Scientific thought leaders*
- *Finance*
- *Business Development*
 - *Partnerships*
 - *Acquisition*
- *Capital Raising*
- *Clinical Trials*
 - *Design*
 - *Studies*
- *Preclinical Trials*
 - *Design*
 - *Studies*
- *Regulatory*
- *IP Protection*

Two Strategies: Build Companies de Novo and roll up

3/13/08



Value Philosophy

We are a growth stock that operates like a value play

We build fundamentally strong companies rather than chasing the next bubble

- CURRENT market opportunity
 - Market risk mitigated
- Minimize technology risk
 - Technology roll-up
 - Platform
 - Multiple opportunities/entry points
- Time to exit/market
- Scalability
- Barriers to Entry
- Growth Potential
- Can we be #1 or #2
 - Not the 99th telecom deal in 2000

3/13/08



Execution: Arrowhead Subsidiaries




3/13/08



INSERT THERAPEUTICS

Improving Drug Performance Through Effective Delivery

Insert's Cyclosert™ is a nano-engineered delivery system that delivers therapeutic agents



Phase I clinical trials underway using Cyclosert™ + off-patent compound, Camptothecin, and Phase II planned for later in 2008

Model: Make “super-generics” and rescue failed compounds for larger companies to sell

3/13/08



Arrowhead Research
CORPORATION

Enhancing The Delivery and Therapeutic Uses of RNAi

RNA interference (RNAi) is a natural mechanism to selectively turn off genes

Calando's delivery molecule self-assembles with siRNA and a targeting agent

siRNA is protected and directed to target tissue



IND Submitted

- **First Targeted siRNA**
- **First Delivered siRNA**
- **First in Oncology**


3/13/08

We believe Tego has a dominant patent portfolio for making and derivatizing fullerenes

Fullerenes are powerful antioxidants

Leveraging IP position and academic Partnerships to address:

Next generation MRI imaging and Treatment for macular degeneration





Engineered Nanomaterials For Solid State Lighting And Solar Cells

Blue LED Market Exceeds \$4B

They offer higher efficiency and longer lifetimes than
conventional light sources

However, current production techniques limit
manufacturing yield and device efficiencies needed for
broader market




3/13/08



Aonex Solution

Simplify production process
Decrease costs



3/13/08



Unidym, Inc.
1430 O'Brien Drive, Suite G
Menlo Park, CA 94025


Tel: (650) 462-1935 | www.unidym.com




Unidym

Carbon for Electronics

Carbon Nanotubes Properties



Carbon nanotube
(CNT)



CNT film



Electrical	1000x more current capacity than copper Faster transistors than silicon
Mechanical	20x stronger than steel
Thermal	Comparable to diamond
Processing	Compatible with inexpensive coating processes
Cost	Comparable to current materials and declining

3/13/08

CNTs Across Industries



Electronics



Materials



Medicine



Energy


3/13/08



Roll-up CNT Technologies & Capabilities



Unidym



Created the dominant player in CNT production and applications

3/13/08



Build a Platform by Building a *Product*

- Leverage materials business for early revenue and development cycle
- Strong growth in flat panel displays, interactive touch film devices and printable/flexible electronics
- CNTs provide a unique fit of solutions, cost and performance benefits in all of these areas
- Replace ITO
- Potential future markets: solar cells, fuel cells, printable electronics



3/13/08



Unique Opportunity

Most disruptive technologies face adoption challenges associated with:

- Market Inertia
- Robustness of Product
- Cost to Incorporate
- Cost of Goods

Unidym's CNT replacement of ITO stands favorably against these

3/13/08



Where Are We Now

- Talented core team
- Maturing subsidiaries
- Approaching monetization
- March 12 close: \$2.46 per share
- We should naturally trade at a multiple of the aggregate value of subs
 - Scalable
 - Significant value in our space and model

3/13/08



ARWR Driving Shareholder Value: 2008

- Maturing subs allow us to shift focus
 - from solely building new companies
 - to monetizing existing subs and building new
- Building a world class team of nanoscientists
- Taking larger roles in building subs
- Consolidating more responsibilities at ARWR
 - Increasing capital efficiency
 - Increasing ability to scale our model
- Streamlining subsidiaries
- Ask every day what is our core competency?
 - What can we uniquely provide to shareholders?
 - New subsidiaries and balanced portfolio

3/13/08



Enhancing Shareholder Value By Restructuring Calando/Insert

- Economies of scale via the merger
 - Similar technologies
 - Cheaper and more efficient development
 - More efficient business development
- ARWR absorbs management
- Scaled back strategy
 - Consolidation within biopharma
 - Expense of drug launch
- Greater value to ARWR shareholders if focus on clinic
- Focus on core competency
- Leverage existing channels via partnerships
 - Transfer marketing expenses
 - Transfer later stage risk

3/13/08



Calando/Insert 2008 Targets

- IND for CALAA-01: March
- Merger: April
- File with the FDA for Phase II IT-101: April
- Partnership for Investigator-led 2nd Phase II IT-101: May
- Partnership for Investigator-led 3^d Phase II IT-101: June
- Enter into industry partnership: Nov
- File new IND: Dec

3/13/08



Aonex & Tego 2008 Targets

Aonex

Sale: August

Tego

AMD lead compound selection: May

Lead MRI contrast agent selection: July

3/13/08



Unidym 2008 Targets

- Life Sciences spin-out: March
- JDA for thin film solar: March
- Sample near production quality for analog-resistive touch panel customers: April
- OLED JDA: July-Sept
- License deal and/or JDA for CNT-enhanced carbon fiber: Sept-Oct
- New JDA LCD supplier(s): Sept-Oct
- Printed electronics JDA: Oct-Nov
- Revenue from CNT-based film sales to analog-resistive touch panel customers: Nov-Dec

3/13/08



Benet Acquisition



3/13/08



Central Issue for Therapeutics: Biological Barriers




- Endothelial and Epithelial Barriers
- Reticulo-Endothelial System (RES)
- Enzymatic Degradation
- Hemo-Rheology
- Tumor-Associated Osmotic & Interstitial Fluid Pressures
- Cell, Endosomal Membrane
- Nuclear Membrane
- Ionic & Molecular Pumps



Reference: M. Ferrari, Cancer Nanotechnologies, Nature Reviews Cancer, March 2005



Leonardo Biosystems

- Focus: Cancer Therapy
- Multi-Stage Vectors
- Strong IP Position




Strategy and Development

- Focus: Breast and Ovarian Cancer
- MSV as platforms for Arrowhead's Nanotech



Competitive Advantages

- Nanoporous Silicon as Platform Material
 - Fully Biodegradable, Harmless
 - Ability to Manufacture in Desired Shape, Size
- Bio-Barrier Avoidance
- Multi-Modal Targeting
- “Personalizing” Therapy by Imaging
- Multiple Waves of Therapy from Same Vector, With Different Subcellular Targets at Predesigned Times



Nanotope

The Next Regeneration

***Opportunity:
Transition from replacement
to enabling regeneration***

3/13/08



Nanotope's Nanofibers: Unique Capabilities

Self Assembly

- *Liquid to solid*
- *Replace surgery with injection*

Mechanical Support

- *Guide scaffolding*

Bioactivity

- *Targeted signals*
- *Sequestered signals*

Biodegradable

Spinal Cord Rationale

- ***Unserved Market***
- ***Compelling Market***
 - Large but not requiring mass marketing***
 - Aggregated Market***
 - Capital already allocated by medical system***
- ***Faster FDA track relative to other treatments***
- ***Understandable and compelling human story***

3/13/08



8-Week Untreated



3/13/08



8-Week Treated



3/13/08



Wound Healing Market

Diabetic Wounds

- >50mm diabetics in major pharmaceutical markets
- >3mm with foot ulcers
- >15% of diabetics will have foot ulcers at some point
- \$1.5bn spent in US on diabetic foot ulcers annually

Bariatric Surgery

- >100,000 in U.S. annually

Surgery for Chronically ill patients

- In US, >1mm patients on hemodialysis, corticosteroids, chemotherapy, or radiation treatment requiring surgery

Cosmetic Surgery


- 11.5mm in US in 2006
- \$12.2 bn in US in 2006

3/13/08




Wounds treated with Nanotope Compound Versus Control (12 days)

*Healed:
Nanotope
Compound*



*Non-healed:
Control*



3/13/08

Peripheral Artery Disease Market

- 20mm in US have PAD
- 20% of people >70yrs have PAD
- Market for peripheral arterial stents is \$3bn in US
- PAD market increases by 43% by 2020
- Reintroducing lost microvasculature is problematic

3/13/08



Growth Story: Other Target Tissues

Reversal/Prevention of Paralysis

Wound Healing

*Stroke/Neurodegenerative
Treatment*

Bone Regeneration

Retinal Regeneration

Myocardial Regeneration

Cartilage Regeneration

*Platform for Stem Cell
Differentiation/Implantation*

3/13/08



Arrowhead Shareholder Value

Unique exposure to growth opportunities

World class nanoscientists on our team

Efficient model

Platform opportunities with focus

3/13/08

